Login

Grants and Non-Dilutive Investments

  • 04 Nov 2014
  • 7:00 PM - 9:45 PM
  • Constant Contact, 1601 Trapelo Rd., 3RD Floor, The Great Room, Waltham (Exit 28, I-95/Route 128)

Meeting Presentations:

Daniel Lilly, Massachusetts Small Business Development Center. Presentation

John Toomey, MBA., Cofounding Shareholder, Celeriss, Inc. Presentation

Dr. Raphael Nir, Ph.D., President and CSO, SBH Science. Presentation


Our November 4th Waltham meeting will explore these issues and others. The panel will focus on getting initial money from alternative sources that are non-or-minimally dilutive. The panelists will speak from experience about these methods and their implications, as well as how to get better results from a very limited amounted of money. You will also have the opportunity to network with other attendees considering these very issues and to directly ask questions of our speakers.

Panel:

Daniel Lilly, Massachusetts Small Business Development Center, http://www.msbdc.org/

Dan’s experience includes program management and technology sales management to the government and to Fortune 500 businesses. He spent seven years of his career as state director of the Rhode Island Procurement Technical Assistance Center. During that time, Dan was credited with rebuilding that program into one of the most productive in the region. In 1995, Rhode Island Governor Lincoln Almond proclaimed a November day "Dan Lilly Day" to recognize him for consistently exceeding program goals, improving state purchasing practices and implementing strategy. In 1997, Dan received a "Special Recognition Award" from the Association of Government Marketing Assistance Specialists (AGMAS) to acknowledge his efforts and dedication to strengthening the PTAC program on a national level. He was also recognized for his work in the National Performance Review. Dan is a member of APTAC, and served as National Legislative Director for the organization from 1995-1998. Dan is the recipient of APTAC the “Fellow” Lifetime Achievement Award.  Dan is a graduate of Fordham University (Bronx, NY) and holds an MBA from the University of Massachusetts, Dartmouth.

 

 


John Toomey, MBA., Cofounding Shareholder, Celeriss, Inc.

www.celeriss.com, LinkedIn: http://www.linkedin.com/in/johnetoomey/,

John is currently CEO and one of three founding shareholders of Celeriss, Inc., an innovative broadband solution company. Prior to this he was CEO of Visible Inventory, Inc., a startup company using sensor based technology to manage and control inventory. In a turnaround situation the company raised funding and reengineered the products for the targeted markets. Visible Inventory was sold to its largest customer and now has a large installed base of it products. John was also one of three founding shareholders of White Mountain DSP, Inc., a technology startup taken to a mature company and subsequently acquired by Analog Devices, Inc. John has held senior management positions at Warren Power Systems, Inc., GCA Corporation and Baird Corporation, all technology based companies.

 


Dr. Raphael Nir, Ph.D., President and CSO, SBH Sciences http://www.sbhsciences.com/ and http://www.sky-ventures.com

Dr. Nir, is an entrepreneur, angel investor and scientist with over 24 years of experience commercializing medical technologies and building successful business. He has held leadership roles in biotech companies ranging from start-ups to publicly-traded corporations.

He received his PhD from Tel-Aviv University (Biotechnology; 1990) and Master in Management (1997; NJIT). Since 1997, he serves as the president and CSO of SBH Sciences where he manages all company’s R&D activities.

Dr. Nir is also the Co-Founder of 5 biotech companies including Karyopharm (Nasdaq:KPTI), SBH Diagnostics, Woodland Biosciences and Alma Bio Therapeutics.

 

 


Jennifer Jordan, Vice President

Jennifer is a venture capitalist focused on early-stage and seed investment in Massachusetts high technology companies.  Her most recent investments are focused on enterprise, big data, and the intersection of biology and IT.  Jennifer has been a member of the Golden Seeds angel investor network, provided start-up mentoring for entrepreneurs through Springboard and the MIT Entrepreneurship Center, and served as Entrepreneurship Lead for the MIT Accelerating Information Technology Innovation program sponsored by Google in Cali, Colombia, where she lead 30 young entrepreneurs in a six week lean start-up program to form ten new mobile technology companies.

Previously, Jennifer served as Corporate Vice President of Investor Relations at Cadence Design Systems and spent 10 years as a Senior Vice President and Senior Equity Research Analyst with Black & Company through its acquisition by Wells Fargo Securities.  She is a black belt in the Indonesian Martial Art of Poekoelan Tjimindie Tulen and holds the title Mas Goeroe.  Jennifer earned an MBA from MIT Sloan and a Bachelor of Arts from Reed College.

 

 

Moderator:


Praveen Bansal, M.S, CEO, TFC BioSciences

 

Praveen Bansal is the Founder and CEO of TFC BioSciences, Inc., a Worcester-based life sciences company with a mission to develop and commercialize smart tools for Drug Discovery. Prior to founding TFC BioSciences, she served as the Program Manager for the ADME/Tox market segment at Tecan, Inc., responsible for the development and global commercialization of fully validated, automated ADME/Tox platform solutions to market. She also held multiple positions at Millennium Pharmaceuticals in drug discovery and development. Prior to Millennium, she was involved with oncology target research at ImmunoGen.

 

 

Coorganizer:


Mila Ayash-Rashkovsky, PhD, Senior Scientist, Shire Pharmaceutical, http://www.shire.com/shireplc/en/home

 

In her current position as a Senior Scientist in Bioanalytical and Biomarker Discovery group at Shire, Mila leads the program to investigate the patient immunogenic reactions to therapeutic proteins to address questions of immunogenicity and anti-drug antibody response. Prior to joining Shire, Mila worked at EMD Serono developing immunization strategies and an antigen specific, single B cell cloning platform for the Antibody Discovery Group.

 Mila received her PhD in Immunology from the Hadassah Medical School of Hebrew University of Jerusalem and did a Post-Doctoral fellowship in the Cancer Immunology and AIDS Department of Dana Farber Cancer Institute, Harvard Medical School.